# Sermorelin Dosage in the Research Literature: Studied Doses and Routes > Sermorelin dosage as studied, not prescribed: the doses, routes, and durations used in published GHRH(1-29) research, the acetate salt form, and reconstitution handling. No human dosing recommendations. The doses, routes, and durations recorded in published GHRH(1-29) studies — reported as study parameters, never as instructions. ## The short version This page logs the **sermorelin dosage** numbers that appear in published studies — what researchers gave, to which population, by which route, for how long. It is a record, not a recommendation. Sermorelin is a research peptide supplied for laboratory work, and this site gives no human dosing instructions. Wherever a number appears, read it as "studied at X in [population], reported in [study]" — not as a protocol to follow. The recurring frame across the literature is subcutaneous (under-the-skin) injection of the lyophilized (freeze-dried) acetate salt, dosed in the evening to track the body's natural overnight growth-hormone pulse. ## Doses used in studies Across the published record, the [doses used in studies](/dosage) cluster by purpose, and the units shift between weight-based microgram/kg dosing (in children) and fixed milligram dosing (in adult research). In the pediatric growth-hormone-deficiency efficacy work, the regimen was 30 micrograms/kg/day subcutaneously at bedtime [1]. In the aging research, healthy older men (mean 68 years) received 0.5 mg and 1 mg subcutaneously twice daily for 14 days; the higher dose produced the GH and IGF-1 values that matched young men, while the lower dose produced a smaller, dose-related rise [2]. For diagnostic and pharmacokinetic work the route shifts to intravenous. A single intravenous bolus (commonly around 1 microgram/kg) was historically used to test pituitary GH reserve, and a dedicated PK study found that intravenous doses of 0.25-2 micrograms/kg elicited GH release in healthy men, with maximal release at 1-2 micrograms/kg [3]. In short children with normal GH secretion, the studied dose was 5 micrograms/kg subcutaneously each evening for six months [8]. These are study parameters, reported as recorded — the range exists because each study targeted a different endpoint in a different population, not because there is a single "correct" research dose. ## How the dose tracks the purpose Reading the numbers together, a pattern emerges: the dose follows the question. Diagnostic and pharmacokinetic studies used small single intravenous boluses, because the goal was to provoke and measure a single GH response, not to sustain an effect [3]. Pediatric growth studies used larger weight-based daily subcutaneous doses sustained over months, because the endpoint — linear growth — accumulates slowly [1][8]. Adult-axis studies used fixed milligram subcutaneous doses twice daily over two weeks, because the endpoint was the 24-hour GH/IGF-1 profile [2]. The drug-class body-composition trials used a stabilized analog at a fixed daily dose over many weeks [6]. None of this constitutes a protocol for any individual; it is a map of how researchers matched dose, route, and duration to the outcome they were measuring. ## Routes studied Subcutaneous injection is the primary research route for sustained dosing [1][2]. Intravenous administration appears in the diagnostic and pharmacokinetic literature, where a bolus is used to probe pituitary reserve and to characterize clearance [3]. The intranasal route was studied historically and is instructive about why injection dominates: in the same PK study, intranasal GHRH(1-29) showed a bioavailability of only about 3-5% [3]. That low mucosal absorption is consistent with the broader observation that peptides are poorly absorbed across mucosa and degraded in the gut, which is why oral, sublingual, and troche formulations are widely criticized in research-user discussion as ineffective. ## Sermorelin acetate: the lyophilized salt form **Sermorelin acetate** is the salt form in which the peptide is supplied — a lyophilized (freeze-dried) white powder. The acetate counterion and the dry state both serve stability: aqueous peptide solutions are susceptible to degradation, which is why GHRH(1-29) is supplied as a lyophilized powder rather than a ready-made liquid. In research handling, the lyophilized powder is reconstituted with a sterile diluent and, once reconstituted, typically refrigerated. Compounded preparations are prepared under USP <797> sterile-compounding standards. The molecular details on the label: molecular formula C149H246N44O42S, molecular weight 3357.9 Da, CAS 86168-78-7 for the peptide (114466-38-5 for the acetate). None of this is a use instruction; it is the handling and identity record for the material. ## Why bedtime dosing appears in the protocols Research protocols frequently place administration at bedtime. The reason is physiologic timing: GH is secreted in pulses concentrated during slow-wave sleep, and GHRH itself promotes slow-wave sleep, so evening administration aligns the stimulus with the body's natural nocturnal GH rhythm. The pediatric efficacy regimen was dosed at bedtime [1], the short-stature study dosed each evening [8], and the GHRH-analog cognition trial dosed before bedtime [6]. The pattern is consistent across the literature — reported here as a study-design feature, not a personal schedule. ## Study durations on record Durations vary widely and resist a single number. The adult GH/IGF-1 reversal study ran 14 days [2]; the short-stature growth study ran six months [8]; the GHRH-analog cognition and body-composition trial ran 20 weeks [6]; pediatric growth was assessed across the first year of therapy [1]. There is no single established treatment duration in the literature — the studied window depends entirely on the endpoint being measured. --- The GHRH(1-29) record stencilled onto raw concrete — the pulsatile-GH mechanism, the studied doses, the body-composition data filed where it belongs as tesamorelin, the formerly-approved-then-withdrawn history set straight, and the thin adult-safety line sprayed in caution-orange; no clinic behind the wall and nothing here dosed, compounded, or sold.